Copyright © 2021 Pharmascimed. All Rights Reserved.
Roche
Roche buys gene therapy company Spark for $4.3bn
- February 25, 2019
- 0
Roche and Spark Therapeutics have announced they are to enter a definitive merger agreement for Roche to fully acquire Spark for $4.3bn - the first company to gain approval for...
Read more
NICE gives Roche’s Perjeta nod for breast cancer
- February 18, 2019
- 0
Roche has bagged NICE backing for Perjeta (pertuxumab) in the prevention of early-stage HER2-positive breast cancer from recurring after surgery, after three attempts. The new draft guidance permits Perjeta to be given...
Read more
Roche submits Kadcyla for real-time FDA review
- February 5, 2019
- 0
Roche is aiming to hasten use of its breast cancer drug Kadcyla with the submission to the FDA under the Real-Time Oncology Review and Assessment Aid programme. Kadcyla (trastuzumab emtansine)...
Read more